

**RE: John H. Krystal, MD  
2010-2011 Financial Disclosure**

**Consultant**

**Note: – The Individual Consultant Agreements listed below are less than \$10,000 per year**

Aisling Capital, LLC  
AstraZeneca Pharmaceuticals  
Biocortech  
Brintnall & Nicolini, Inc.  
Easton Associates  
Gilead Sciences, Inc.  
GlaxoSmithKline  
Janssen Pharmaceuticals  
Lundbeck Research USA  
Medivation, Inc.  
Merz Pharmaceuticals  
MK Medical Communications  
F. Hoffmann-La Roche Ltd  
SK Holdings Co., Ltd  
Sunovion Pharmaceuticals, Inc.  
Takeda Industries  
Teva Pharmaceutical Industries, Ltd.

**Scientific Advisory Board**

Abbott Laboratories  
Bristol-Myers Squibb  
Eisai, Inc.  
Eli Lilly and Co.  
Forest Laboratories, Inc.  
Lohocla Research Corporation  
Mnemosyne Pharmaceuticals, Inc.  
Naurex, Inc.  
Pfizer Pharmaceuticals  
Shire Pharmaceuticals

**Exercisable Warrant Options**

Tetragenex Pharmaceuticals (value less than \$350)

**Board of Directors:**

Coalition for Translational Research in Alcohol and Substance Use Disorders

**President Elect :**

American College of Neuropsychopharmacology

**Research Support to Department of Veterans Affairs**

Janssen Research Foundation (Provided drug and some study support to the Department of Veterans Affairs)

**Editorial Board**

**Income Greater than \$10,000**

Editor - Biological Psychiatry

**Employment:**

Yale University School of Medicine  
VA CT Healthcare System

## **Patents and Inventions**

- 1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. Patent #:5,447,948. September 5, 1995
- 2) I am a co-inventor with Dr. Gerard Sanacora on a filed patent application by Yale University related to targeting the glutamatergic system for the treatment of neuropsychiatric disorders (PCTWO06108055A1).
- 3) Intranasal Administration of Ketamine to Treat Depression (pending)